Human Herpesvirus-8 Disease Flashcards

(50 cards)

1
Q

What is the estimated seroprevalence of human herpesvirus-8 (HHV-8) in the general U.S. population?

A

1% to 5%

This compares to 10% to 20% in certain Mediterranean countries and 30% to 80% in parts of sub-Saharan Africa.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which groups are at increased risk for HHV-8 infection in the United States?

A

Men who have sex with men (MSM) and persons with HIV infection

Among MSM without HIV, seroprevalence ranges from 13% to 20%, increasing to 30% to 35% among MSM with HIV.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What diseases are etiologically associated with HHV-8?

A

Kaposi sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman’s disease (MCD)

KS includes classic, endemic, transplant-related, and AIDS-related forms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the increased risk of developing Kaposi sarcoma for patients with HHV-8 viremia?

A

Approximately nine-fold

This is relative to those without HHV-8 viremia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the overall prevalence of Kaposi sarcoma in the U.S. among patients with AIDS before effective antiretroviral therapy (ART)?

A

As high as 30%

The incidence rose steeply between 1981 and 1987, then gradually declined.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What factors contributed to the reduction in Kaposi sarcoma incidence prior to widespread ART availability?

A
  • Deaths of patients with advanced AIDS
  • Increasing use of antiviral drugs

Antiviral drugs included zidovudine, ganciclovir, foscarnet, and cidofovir.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

True or False: Kaposi sarcoma is one of the most common cancers among the AIDS population in the U.S.

A

True

HIV infection increases the risk of KS several thousand fold even in the ART era.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the common clinical manifestations of Kaposi sarcoma?

A
  • Nontender, hyperpigmented skin lesions
  • Oral lesions
  • Lymphatic involvement
  • Visceral involvement

Oral lesions occur in approximately one-third of patients and may predict pulmonary involvement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the characteristic presentation of primary effusion lymphoma (PEL)?

A

Effusions isolated within pleural, pericardial, or abdominal cavities

Mass lesions and ‘extracavitary’ disease may also occur.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the systemic symptoms associated with multicentric Castleman’s disease (MCD)?

A
  • Fever
  • Night sweats
  • Generalized adenopathy
  • Hepatosplenomegaly

MCD may mimic other inflammatory conditions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the role of serologic testing for HHV-8 antibodies in diagnostics?

A

Currently not indicated for diagnostic testing or routine screening

This is due to lack of standardization and poor sensitivity and specificity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the suspected primary mode of transmission for HHV-8?

A

Saliva

Asymptomatic HHV-8 infection is often associated with shedding in saliva.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Fill in the blank: Early initiation of _______ is likely to be the most effective measure for the prevention of Kaposi sarcoma.

A

ART

This is particularly important for HIV-positive individuals.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What chemotherapy agents are preferred for treating Kaposi sarcoma with visceral involvement?

A
  • Liposomal doxorubicin
  • Paclitaxel

Liposomal doxorubicin is preferred due to lower toxicity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is a significant concern when using corticosteroids in patients with Kaposi sarcoma?

A

Potential exacerbation of life-threatening disease

Corticosteroids are associated with the development of KS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the recommended treatments for primary effusion lymphoma?

A
  • Chemotherapy
  • ART

Limited data exists due to the rarity of PEL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What treatment options are available for multicentric Castleman’s disease?

A
  • IV ganciclovir
  • Oral valganciclovir
  • Rituximab

Combination therapies have shown some benefit.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is Immune Reconstitution Inflammatory Syndrome (IRIS)?

A

A condition that may occur among HHV-8-infected patients initiating ART

KS-IRIS can present as unmasking or worsening of KS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the risk factors for developing KS-IRIS?

A
  • Advanced KS tumor stage (T1)
  • Pre-treatment HIV viral load >5 log10 copies/mL
  • Detectable pre-treatment plasma HHV-8
  • Initiation of ART alone without concurrent chemotherapy

KS-IRIS is associated with significant morbidity and mortality.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the risk factors for developing KS-IRIS?

A

Advanced KS tumor stage (T1), pre-treatment HIV viral load >5 log10 copies/mL, detectable pre-treatment plasma HHV-8, initiation of ART alone without concurrent chemotherapy.

KS-IRIS refers to Kaposi’s Sarcoma-Immune Reconstitution Inflammatory Syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the recommended treatment for KS-IRIS?

A

Systemic chemotherapy and supportive measures. Steroids are strongly discouraged.

Corticosteroid therapy has been associated with exacerbation of pre-existing KS in persons with HIV.

22
Q

Is there data on how initiation of ART affects primary effusion lymphoma (PEL)?

A

No data exist on the frequency with which initiation of ART complicates the course of primary effusion lymphoma.

PEL is a type of lymphoma associated with HHV-8.

23
Q

What has been observed in a small number of patients with HIV-associated MCD upon initiation of ART?

A

Clinical decompensation.

MCD stands for Multicentric Castleman Disease.

24
Q

What are the key components of therapy for HHV-8-associated IRIS?

A

Suppression of HIV replication and immune reconstitution.

Initiation of ART should not be delayed.

25
What is the recommendation for ART in patients with active KS?
ART is indicated for all patients with active KS. ## Footnote KS is an AIDS-defining cancer.
26
What is recommended to prevent KS recurrence in patients with HIV?
Effective suppression of HIV replication with ART. ## Footnote This is also recommended for patients with MCD and malignant lymphoproliferative disorders.
27
What is the seroprevalence of HHV-8 infection among pregnant women with HIV in New York City?
Ranges from 1.7% among U.S.-born to 3.6% among Haitian-born women, and up to 11.6% among pregnant women from 4 other U.S. cities. ## Footnote Seroprevalence varies by geographic area.
28
Does pregnancy affect the prevalence of antibodies to HHV-8?
No, pregnancy does not appear to affect the prevalence or antibody levels. ## Footnote However, levels of HHV-8 DNA in peripheral blood may increase late in pregnancy.
29
Is routine screening for HHV-8 by PCR or serology indicated for pregnant women with HIV?
No, routine screening is not indicated. ## Footnote Antiviral therapy for HHV-8 infection in pregnancy is also not recommended.
30
What should be done when KS, PEL, or MCD occur during pregnancy?
Managed with consultations between the obstetrician, infectious disease specialist, and oncologist; treatment may be deferred until after delivery. ## Footnote This is due to the rarity of these conditions in pregnancy.
31
What does in vitro models suggest about beta-human chorionic gonadotropin?
It induces regression of KS tumors. ## Footnote Clinical reports on KS incidence and natural history in pregnancy are conflicting.
32
Is perinatal transmission of HHV-8 common?
Occurs infrequently. ## Footnote Evidence includes cases of KS in infants shortly after birth.
33
What increases the risk of HHV-8 transmission from mother to infant?
Higher maternal antibody titer and levels of HHV-8. ## Footnote Detection of similar strains of HHV-8 DNA in specimens drawn at birth also supports this.
34
What is the mortality rate among infants with HIV born to HHV-8-seropositive mothers compared to seronegative mothers?
Increased mortality through age 24 months. ## Footnote Studies could not completely account for other confounding factors affecting infants with HIV.
35
How does the rate of HHV-8 seropositivity compare between children born to HHV-8 antibody-positive versus antibody-negative women?
Substantially higher rate among children born to antibody-positive women. ## Footnote Multiple studies document this finding.
36
What are strong risk factors for the development of Kaposi Sarcoma (KS)?
Low CD4 cell count and uncontrolled HIV viremia ## Footnote Early initiation of ART is likely the most effective measure for prevention of KS.
37
What is the recommended treatment for mild-to-moderate KS?
Initiation or optimization of ART ## Footnote This is categorized as AII in treatment recommendations.
38
What is the preferred first-line chemotherapy for advanced KS?
Liposomal doxorubicin ## Footnote This is categorized as AI in treatment recommendations.
39
What should be avoided in patients with KS, including those with KS-IRIS?
Corticosteroids ## Footnote Their use can exacerbate life-threatening disease.
40
Are antiviral agents with activity against HHV-8 recommended for KS treatment?
No ## Footnote This is categorized as AIII in treatment recommendations.
41
What is the treatment approach for Primary Effusion Lymphoma (PEL)?
Chemotherapy + ART ## Footnote Consultation with a specialist is recommended.
42
What adjunctive therapies can be used for PEL?
Oral valganciclovir or IV ganciclovir ## Footnote This is categorized as CIII in treatment recommendations.
43
What therapy options should all patients with Multicentric Castleman’s Disease (MCD) receive?
ART ## Footnote This is categorized as AIII in treatment recommendations.
44
What are some therapy options for MCD depending on patient status?
* IV ganciclovir (or oral valganciclovir) +/- high dose zidovudine * Rituximab +/- prednisone * Rituximab + liposomal doxorubicin for concurrent KS * Monoclonal antibody targeting IL-6 or IL-6 receptor ## Footnote Consultation with a specialist is necessary.
45
What caution should be taken regarding corticosteroids in MCD treatment?
They should be used with caution or avoided ## Footnote Especially in patients with concurrent KS.
46
What potential issue may patients experience after receiving rituximab or corticosteroids for MCD?
Subsequent exacerbation or emergence of KS ## Footnote This is an important consideration in treatment planning.
47
What does ART stand for?
Antiretroviral therapy
48
What does PEL stand for?
Primary effusion lymphoma
49
What does MCD stand for?
Multicentric Castleman’s disease
50
What classification is used to categorize KS patients into 'Good Risk' and 'Poor Risk'?
AIDS Clinical Trials Group (ACTG) KS Staging Classification ## Footnote It uses T (Tumor), I (Immune), and S (Systemic illness) criteria.